Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397690 | 0.84 | CHRM3 (0.39) | MAPTNPSR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4401054 | 0.84 | HTT (0.40) | ALDH1A1CHRM3TP53HTTPOLB | |
| SCHEMBL4391982 | 0.82 | CXCR4 (0.44) | MAPTCXCR4ALDH1A1SMN1; SMN2CHRM3 | |
| SCHEMBL4391985 | 0.82 | CXCR4 (0.37) | MAPTCXCR4ALDH1A1SMN1; SMN2CHRM3 | |
| SCHEMBL4401977 | 0.79 | MAPT (0.41) | MAPTALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL4399090 | 0.79 | DRD4 (0.43) | MAPTALDH1A1SMN1; SMN2KDM4ECHRM3 | |
| SCHEMBL4397560 | 0.78 | CASR (0.49) | MAPTALDH1A1SMN1; SMN2LMNACHRM3 | |
| Hydrochloric Acid SCHEMBL4399450 | 0.77 | CASR (0.44) | CYP1A2CYP2D6CYP2C19TP53MEN1 | |
| SCHEMBL4400761 | 0.76 | KMT2A (0.44) | CXCR4ALDH1A1SMN1; SMN2LMNACHRM3 | |
| SCHEMBL4396219 | 0.76 | CHRM3 (0.49) | CXCR4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | MAPT 4227/4885NPSR1 363/4885CYP1A2 129/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | MAPT 3398/4885NPSR1 266/4885CYP1A2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.